Health and Healthcare
Dendreon, When 200% Sales Growth Is Not Enough (DNDN)
Published:
Last Updated:
Thomson Reuters has estimates of -$0.63 EPS and $81.23 million in sales. The company called this report as having exceeded its guidance of low single-digit quarter-over-quarter growth.
Dendreon had approximately $559.1 million in cash, cash equivalents and short-term and long-term investments as of March 31, down from $617.7 at the end of the December 31, 2011 period.
Without formal guidance, we cannot consider this report as “finished business” until that data is out.
Dendreon shares closed up 3.2% at $11.69 against a 52-week range of $6.46 to $42.87, and shares are down 7.3% at $10.82 in the after-hours session.
JON C. OGG
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.